Related trials

ENGAGE-AF TIMI 48 High dose, 2013 - edoxaban vs warfarin standard dose

AVERROES, 2011 - apixaban vs aspirin

ARISTOTLE, 2011 - apixaban vs warfarin standard dose

ROCKET-AF, 2010 - rivaroxaban vs warfarin standard dose

ACTIVE A, 2009 - aspirin + clopidogrel vs aspirin

RE-LY (150mg), 2009 - dabigatran 150mg vs warfarin standard dose

RE-LY (110mg), 2009 - dabigatran 110mg vs warfarin standard dose

Lip (phase 2 AZD0837), 2009 - AZD0837 vs warfarin standard dose

AMADEUS, 2008 - idraparinux vs warfarin standard dose

PETRO (150mg), 2007 - dabigatran 150mg vs warfarin standard dose

Japanese AF Trial, 2006 - aspirin vs control

ACTIVE W, 2006 - aspirin + clopidogrel vs anticoagulant

SPORTIF V, 2005 - ximelagatran vs warfarin standard dose

NASPEAF (triflusal vs coumadin standard dose)), 2004 - triflusal vs coumadin standard dose

NASPEAF (triflusal + coumadin medium dose vs coumadin standard dose), 2004 - triflusal+coumadin medium dose vs coumadin standard dose

NASPEAF (triflusal+coumadin medium dose vs triflusal), 2004 - triflusal+coumadin medium dose vs triflusal

SAFT(warfarin low dose + aspirin vs no treatment), 2003 - warfarin low dose + aspirin vs control

SPORTIF III, 2003 - ximelagatran vs warfarin standard dose

SPORTIF II (ximelagatran vs warfarin standard dose), 2002 - ximelagatran vs warfarin standard dose

PATAF (coumadin low dose vs coumadin standard dose), 1999 - coumadin low dose vs coumadin standard dose

PATAF (vs coumadin standard dose), 1999 - aspirin vs coumadin standard dose

LASAF(aspirin vs no treatment), 1999 - aspirin vs control

PATAF (vs coumadin low dose), 1999 - aspirin vs coumadin low dose

AFASAK II (aspirin vs warfarin low dose), 1998 - aspirin vs warfarin low dose

AFASAK II (warfarin low dose+aspirin vs warfarin standard dose), 1998 - warfarin + aspirin vs warfarin standard dose

LASAF(aspirin vs no treatment) study, 1999	TRC2629
	download pdf: aspirin | antithrombotics for atrial fibrillation

Treatments

Studied treatment	aspirin:125mg/day(group A1);125mg on alternate days(group A2)
Control treatment	no control treatment(group C)

Patients

Method and design

Randomized effectives	NA / NA (studied vs. control)
Blinding	Open

Results

No results available for this trial - no clinical endpoint reported

Meta-analysis of all similar trials:

antithrombotics in atrial fibrillation for primary prevention of thromboembolic events

Reference(s)

TrialResults-center ID	TRC2629
Trials register #	NA